My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 436

    1.

    Enhancing incretin action for the treatment of type 2 diabetes.

    Drucker DJ.

    Diabetes Care. 2003 Oct;26(10):2929-40. Review.PMID: 14514604 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.

    Baggio LL, Drucker DJ.

    Treat Endocrinol. 2002;1(2):117-25. Review.PMID: 15765627 [PubMed - indexed for MEDLINE]Related articles

    3.

    [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2]

    Diamant M, Bunck MC, Heine RJ.

    Ned Tijdschr Geneeskd. 2004 Sep 25;148(39):1912-7. Review. Dutch. PMID: 15495988 [PubMed - indexed for MEDLINE]Related articles

    4.

    Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.

    Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C.

    Diabetes Metab. 2005 Jun;31(3 Pt 1):233-42. Review.PMID: 16142014 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

    Green BD, Gault VA, O'harte FP, Flatt PR.

    Curr Pharm Des. 2004;10(29):3651-62. Review.PMID: 15579061 [PubMed - indexed for MEDLINE]Related articles

    6.

    [The incretin effect: a new therapeutic target in type 2 diabetes]

    Féry F.

    Rev Med Brux. 2007 Sep;28(4):329-35. French. PMID: 17958029 [PubMed - indexed for MEDLINE]Related articles

    7.

    Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.

    Holst JJ, Deacon CF.

    Diabetes. 1998 Nov;47(11):1663-70. Review.PMID: 9792533 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.

    Hansotia T, Drucker DJ.

    Regul Pept. 2005 Jun 15;128(2):125-34. Review.PMID: 15780432 [PubMed - indexed for MEDLINE]Related articles

    9.

    Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.

    Meier JJ, Gallwitz B, Nauck MA.

    BioDrugs. 2003;17(2):93-102. Review.PMID: 12641488 [PubMed - indexed for MEDLINE]Related articles

    10.

    Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.

    Drucker DJ.

    Curr Pharm Des. 2001 Sep;7(14):1399-412. Review.PMID: 11472275 [PubMed - indexed for MEDLINE]Related articles

    11.

    Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.

    Siddiqui NI.

    Mymensingh Med J. 2009 Jan;18(1):113-24. Review.PMID: 19182763 [PubMed - indexed for MEDLINE]Related articles

    12.

    Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

    Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ.

    J Endocrinol. 2002 Feb;172(2):355-62.PMID: 11834453 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.

    Mest HJ, Mentlein R.

    Diabetologia. 2005 Apr;48(4):616-20. Epub 2005 Mar 16.PMID: 15770466 [PubMed - indexed for MEDLINE]Related articles

    14.

    Gut peptides in the treatment of diabetes mellitus.

    Vahl TP, D'Alessio DA.

    Expert Opin Investig Drugs. 2004 Mar;13(3):177-88. Review.PMID: 15013938 [PubMed - indexed for MEDLINE]Related articles

    15.

    Incretins and other peptides in the treatment of diabetes.

    Todd JF, Bloom SR.

    Diabet Med. 2007 Mar;24(3):223-32. Review.PMID: 17263764 [PubMed - indexed for MEDLINE]Related articles

    16.

    The entero-insular axis: implications for human metabolism.

    Ranganath LR.

    Clin Chem Lab Med. 2008;46(1):43-56. Review.PMID: 18020966 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.

    Green BD, Gault VA, O'Harte FP, Flatt PR.

    Diabetes Obes Metab. 2005 Sep;7(5):595-604.PMID: 16050953 [PubMed - indexed for MEDLINE]Related articles

    18.

    Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.

    Green BD, Gault VA, Flatt PR, Harriott P, Greer B, O'Harte FP.

    Arch Biochem Biophys. 2004 Aug 15;428(2):136-43.PMID: 15246869 [PubMed - indexed for MEDLINE]Related articles

    19.

    Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.

    Langley AK, Suffoletta TJ, Jennings HR.

    Pharmacotherapy. 2007 Aug;27(8):1163-80. Review.PMID: 17655515 [PubMed - indexed for MEDLINE]Related articles

    20.

    [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)]

    Kluz J, Adamiec R.

    Postepy Hig Med Dosw (Online). 2006;60:15-23. Review. Polish. PMID: 16407790 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity